| Exercise to Boost Response to Checkpoint Blockade Immunotherapy (NCT05358938) | H. Lee Moffitt Cancer Center and Research Institute | 2022-06-21 |
| Study To Evaluate The Safety, Tolerability And Immunogenicity Of 4 mg Of ITI-3000 In Patients With Polyomavirus-Positive Merkel Cell Carcinoma (MCC) (NCT05422781) | Immunomic Therapeutics, Inc. | 2022-06-13 |
| MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors (NCT05076760) | Memgen, Inc. | 2022-04-21 |
| Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO (NCT05078047) | UNICANCER | 2022-03-08 |
| Hypofractionated Radiation Therapy for Merkel Cell Carcinoma (NCT05100095) | M.D. Anderson Cancer Center | 2021-12-14 |
| A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer (NCT04916002) | Regeneron Pharmaceuticals | 2021-11-30 |
| Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic Merkel Cell Carcinoma (MERKLIN 1) (NCT04874831) | 4SC AG | 2021-11-01 |
| Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma (NCT04975152) | H. Lee Moffitt Cancer Center and Research Institute | 2021-10-22 |
| A Beta-only IL-2 ImmunoTherapY Study (NCT05086692) | Medicenna Therapeutics, Inc. | 2021-08-27 |
| Personalised Immunotherapy Platform (NCT06536257) | Melanoma Institute Australia | 2021-06-08 |
| Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma (NCT04869137) | H. Lee Moffitt Cancer Center and Research Institute | 2021-05-28 |
| Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer (NCT04590781) | Xencor, Inc. | 2021-05-10 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors (NCT04272034) | Incyte Corporation | 2021-03-26 |
| Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma (NCT04792073) | Memorial Sloan Kettering Cancer Center | 2021-03-08 |
| A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors (NCT04725331) | Transgene | 2021-02-25 |
| TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy (NCT04596033) | Genocea Biosciences, Inc. | 2020-11-11 |
| Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma (NCT04291885) | Melanoma and Skin Cancer Trials Limited | 2020-10-26 |
| Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1 (NCT04393753) | 4SC AG | 2020-10-13 |
| A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers (NCT04260802) | Ocellaris Pharma, Inc. | 2020-09-24 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors (NCT04242199) | Incyte Corporation | 2020-09-04 |
| Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies (NCT04349436) | Replimune, Inc. | 2020-05-15 |
| Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers (NCT04160065) | TuHURA Biosciences, Inc. | 2020-03-03 |
| QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy (NCT03853317) | ImmunityBio, Inc. | 2020-02-19 |
| LITT and Pembrolizumab in Recurrent Brain Metastasis (NCT04187872) | University of Florida | 2020-01-10 |
| High-Risk Skin Cancers With Atezolizumab Plus NT-I7 (NCT03901573) | NeoImmuneTech | 2019-12-26 |
| Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers (NCT03935893) | Udai Kammula | 2019-12-03 |
| Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors (NCT04116320) | Craig L Slingluff, Jr | 2019-11-21 |
| Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors (NCT04157985) | Dan Zandberg | 2019-11-15 |
| A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell Carcinoma (NCT04047251) | Fujifilm Pharmaceuticals U.S.A., Inc. | 2019-11-14 |
| Palliative RT & Anti-PD-1/PD-L1 Checkpoint Blockade in Metastatic Merkel Cell Carcinoma (NCT03988647) | Stanford University | 2019-07-24 |
| Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors (NCT04234113) | SOTIO Biotech AG | 2019-06-13 |
| Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy (NCT04106167) | Fate Therapeutics | 2019-06-11 |
| Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma (NCT03787602) | Kartos Therapeutics, Inc. | 2019-03-19 |
| Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913) (NCT03783078) | Merck Sharp & Dohme LLC | 2019-02-25 |
| FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors (NCT03841110) | Fate Therapeutics | 2019-02-15 |
| Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer (NCT03798639) | Claire Verschraegen | 2019-01-07 |
| QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors (NCT03228667) | ImmunityBio, Inc. | 2018-12-11 |
| A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies (NCT03652077) | Incyte Corporation | 2018-09-24 |
| A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies (NCT03629756) | Arcus Biosciences, Inc. | 2018-07-24 |
| DOTATOC PET/CT for Imaging NET Patients (NCT03583528) | British Columbia Cancer Agency | 2018-07-11 |
| A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies (NCT03538028) | Incyte Biosciences International Sàrl | 2018-06-18 |
| T-VEC in Non-melanoma Skin Cancer (NCT03458117) | University of Zurich | 2018-04-19 |
| REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies (NCT03435640) | Nektar Therapeutics | 2018-03-15 |
| QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy (NCT03167164) | ImmunityBio, Inc. | 2017-12-01 |
| Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor (NCT02831179) | Vanderbilt-Ingram Cancer Center | 2017-12-01 |
| How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes (NCT03370861) | Washington University School of Medicine | 2017-11-08 |
| Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers (NCT02978625) | National Cancer Institute (NCI) | 2017-09-27 |
| Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers (NCT03212404) | Checkpoint Therapeutics, Inc. | 2017-09-20 |
| Lymph Node Identification in Skin Malignancy Using ICG Transcutaneously Study (NCT03545334) | Insel Gruppe AG, University Hospital Bern | 2017-09-01 |
| Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma (NCT03071406) | H. Lee Moffitt Cancer Center and Research Institute | 2017-03-14 |
| A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers (NCT02643303) | Ludwig Institute for Cancer Research | 2016-12-28 |
| Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides (NCT02890368) | Pfizer | 2016-09-01 |
| A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors (NCT02819843) | Memorial Sloan Kettering Cancer Center | 2016-06-21 |
| Comparing Radical Surgery and Radical Radiotherapy as First Definitive Treatment for Primary MCC (NCT05253144) | University of Birmingham | 2016-03-19 |
| French National Database of Rare Dermatological Cancers (NCT03210935) | University Hospital, Lille | 2015-11-24 |
| MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma (NCT02514824) | Dana-Farber Cancer Institute | 2015-10-01 |
| Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus (NCT02479698) | M.D. Anderson Cancer Center | 2015-07-23 |
| Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With Immune Checkpoint Blocking Antibodies vs Observation (NCT02196961) | Prof. Dr. med. Dirk Schadendorf | 2014-06-01 |
| Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma (NCT02036476) | Dana-Farber Cancer Institute | 2014-02-01 |
| A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell Carcinoma (NCT02035657) | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2014-01-01 |
| F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma (NCT02054884) | Philogen S.p.A. | 2013-10-25 |
| Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma (NCT01913691) | National Cancer Institute (NCI) | 2013-07-09 |
| IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell Cancer (NCT01440816) | OncoSec Medical Incorporated | 2012-01-03 |
| Merkel Positron Emission Tomography (PET) Protocol (NCT01013779) | Trans Tasman Radiation Oncology Group | 2009-12-01 |
| Videoscopic Versus Open Inguinal Lymphadenectomy for Cancer (NCT01526486) | Emory University | 2009-06-01 |
| The Impact of Total Body Skin Examination on Skin Cancer Detection (NCT00765193) | Medical University of Graz | 2008-05-01 |
| BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors (NCT00346385) | ImmunoGen, Inc. | 2002-03-01 |
| Optical Biopsy of Human Skin in Conjunction With Laser Treatment (NCT00540566) | University of California, Irvine | 1999-06-01 |
| IFx-Hu2.0 Expanded Access Program (NCT04853602) | TuHURA Biosciences, Inc. | |
| Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy (NCT00003514) | Burzynski Research Institute | |